Epidiolex, a new pharmaceutical drug containing CBD Isolate opens up a new era of cannabinoid medicine and cannabis reform. CBD Isolate Anti-Epilepsy Drug Epidiolex Approved by FDA On June 25, 2018, the United States Food & Drug Administration (FDA) approved EPIDIOLEX® – a CBD isolate-based oral solution for the treatment of seizures associated with two severe epilepsy syndromes – […]
Pharma Grade CBD Products to be Rescheduled to Schedule V Pharma Grade CBD Products such as Epidiolex will be Schedule V – comparable to codeine-containing cough syrups – indicating a low potential for abuse and effectiveness as a therapeutic drug. The Drug Enforcement Agency published a notification on the FDA CBD rescheduling in the Federal Register.
CBD Isolate Drugs Rescheduled by the FDA CBD isolate based drug Epidolex has been removed from Schedule I and placed in Schedule V which will make access to the drug much simpler for patients who can afford it. The rescheduling is a major breakthrough in the medical cannabis and hemp CBD industry because it finally
